Table 3.
A summary on clinical trials of cancer immunotherapies in combinatorial drug treatments for cancer patients.
| Trial Name | Trial Phase/Clinical Trails Number | Target Indication | Therapeutic Approach | Key Outcomes/Summary | References |
|---|---|---|---|---|---|
| KEYNOTE-189 | Phase 3 NCT02578680 | NSCLC | ICI (pembrolizumab + chemo) | ORR: 48%, PFS: 9.0 mo, OS: 22.4 mo | (143, 147) |
| JULIET | Phase 2 NCT02445248 | DLBCL | CAR-T (tisagenlecleucel) | ORR: 53%, DCR: 80% | (144) |
| CheckMate 067 | Phase 3 NCT01844505 |
melanoma | ICI (nivolumab + ipilimumab) | ORR: 57%, PFS: 11.5 mo, OS: 58% | (142) |
| IMpower150 | Phase 3 NCT02366143 |
NSCLC | ICI (atezolizumab + carboplatin + paclitaxel) | ABCP significantly improved OS compared to BCP, including in patients with EGFR/ALK mutations and liver metastases (ORR: 45%, PFS: 8.3 mo, OS: 19.4 mo) | (146, 153) |
| ZUMA-2 | Phase 2 NCT02601313 |
follicular lymphoma | CAR-T (axicabtagene ciloleucel) | Single infusion of KTE-X19 led to durable responses in patients who had failed previous therapies, including BTK inhibitors (ORR: 95%, DCR: 100%) | (148, 154) |
| CHECKMATE-9ER | Phase 2 NCT03141177 |
Advanced renal cell carcinoma | Nivolumab + cabozantinib vs. sunitinib | Combination therapy demonstrated significant improvements in OS, and response rates with manageable safety profile (Median PFS: 16.6 months vs. 8.3 months; ORR: 55.7% vs. 27.1%) | (145, 151, 155) |
| TRANSCEND NHL 001 | Phase 2 NCT02631044 |
NHL | CAR-T (lisocabtagene maraleucel) | ORR: 74%, DCR: 93% | (152) |
| KEYNOTE-522 | Phase 2 NCT03036488 |
Triple-negative breast cancer | Pembrolizumab + chemotherapy vs. placebo + chemotherapy (neoadjuvant followed by adjuvant) | Addition of pembrolizumab to neoadjuvant chemotherapy significantly increased pCR rates and improved event-free survival in early TNBC (pCR rate: 64.8% (pembrolizumab) vs. 51.2% (placebo); 3-year EFS: 84.5% vs. 76.8%) | (142, 149, 150) |
NSCLC, Non-Small Cell Lung Cancer; mCRC, Metastatic Colorectal Cancer; RCC, Renal Cell Carcinoma; NHL, Non-Hodgkin Lymphoma; AML, Acute Myeloid Leukemia; ICI, Immune Checkpoint Inhibitor; CAR-T, Chimeric Antigen Receptor T-cell therapy; mAb, Monoclonal antibody; OV, Oncolytic virus; ORR, Overall Response Rate; PFS, Progression-Free Survival; OS, Overall Survival; DCR, Disease Control Rate.